Liquidia infringes two United Therapeutics patent claims in Yutrepia case, judge rules
LQDA•A Delaware federal court ruled that Liquidia’s YUTREPIA infringed two valid claims of a United Therapeutics patent, while finding other asserted claims invalid. The parties must propose a judgment within one week, including remedies; Liquidia plans to appeal.
1. Patent ruling and next steps
The court found that YUTREPIA infringed claims 1 and 14 of United Therapeutics’ U.S. Patent No. 11,826,327 and upheld those claims as valid, while ruling other asserted claims invalid. The parties must submit a proposed judgment within one week, including remedies that could remove YUTREPIA’s PH-ILD indication or place broader limits on its market availability. Liquidia plans to appeal, saying it disagrees with the ruling on the two upheld claims.
